Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies (Nasdaq: ADPT) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management is scheduled to present on Monday, January 12, 2026 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast will be available on the company’s Investors website at www.adaptivebiotech.com.
Details
News Market Reaction – ADPT
On Dec 31, the first trading day after this news, ADPT closed 1.10% below the previous close.
Data tracked by StockTitan Argus for the Dec 31 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 12, 2026
- Scheduled company presentation
- Presentation time PT
- 4:30 p.m.
- Scheduled Pacific Time slot
- Presentation time ET
- 7:30 p.m.
- Scheduled Eastern Time slot
Historical Context
-
Two non-exclusive immune receptor licensing agreements with Pfizer in RA.
-
Jefferies fireside chat on MRD and clonoSEQ assay technology.
-
clonoSEQ MRD featured in 89 ASH abstracts, including 36 oral talks.
-
Planned participation in Jefferies Global Healthcare and Piper Sandler conferences.
-
Q3 2025 results with strong MRD growth and raised MRD guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Adaptive Biotechnologies’ management is scheduled to present on Monday, January 12, 2026, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.